Insights Into Cataract Surgery Outcomes In Age-Related Macular Degeneration: Real-World Perspectives Across Severity Grades

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Ophthalmol Ther

Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D

doi: 10.1007/s40123-025-01140-z

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Macular Diseases

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Br J Ophthalmol

Vu TA, Fenwick EK, Man REK, Thakur S, Tan ACS, Cheung CMG, Gupta P, Lamoureux EL

doi: 10.1136/bjo-2024-325713

Macular Diseases

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Ophthalmol Retina

Steinle NC, McCullough AJ, Silva FQ, Du W, Moini H, Singh RP

doi: 10.1016/j.oret.2024.12.018

Macular Diseases

Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Ophthalmology

Nanji K, Grad J, Hatamnejad A, McKechnie T, Phillips M, Cheung CMG, Patel PJ, Marco RD, Borrelli E, Steel DH, Sadda SR, Wong TY, Sivaprasad S, Guymer R, Wykoff CC, Chaudhary V

doi: 10.1016/j.ophtha.2025.06.018

Related content

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis